1. Home
  2. SPRO vs TUSK Comparison

SPRO vs TUSK Comparison

Compare SPRO & TUSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • TUSK
  • Stock Information
  • Founded
  • SPRO 2013
  • TUSK 2014
  • Country
  • SPRO United States
  • TUSK United States
  • Employees
  • SPRO N/A
  • TUSK N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • TUSK Oilfield Services/Equipment
  • Sector
  • SPRO Health Care
  • TUSK Energy
  • Exchange
  • SPRO Nasdaq
  • TUSK Nasdaq
  • Market Cap
  • SPRO 110.9M
  • TUSK 131.4M
  • IPO Year
  • SPRO 2017
  • TUSK 2016
  • Fundamental
  • Price
  • SPRO $2.13
  • TUSK $2.29
  • Analyst Decision
  • SPRO Buy
  • TUSK
  • Analyst Count
  • SPRO 4
  • TUSK 0
  • Target Price
  • SPRO $5.00
  • TUSK N/A
  • AVG Volume (30 Days)
  • SPRO 308.6K
  • TUSK 116.1K
  • Earning Date
  • SPRO 11-13-2025
  • TUSK 10-31-2025
  • Dividend Yield
  • SPRO N/A
  • TUSK N/A
  • EPS Growth
  • SPRO N/A
  • TUSK N/A
  • EPS
  • SPRO N/A
  • TUSK N/A
  • Revenue
  • SPRO $48,576,000.00
  • TUSK $188,567,000.00
  • Revenue This Year
  • SPRO N/A
  • TUSK N/A
  • Revenue Next Year
  • SPRO N/A
  • TUSK $28.22
  • P/E Ratio
  • SPRO N/A
  • TUSK N/A
  • Revenue Growth
  • SPRO N/A
  • TUSK 26.46
  • 52 Week Low
  • SPRO $0.51
  • TUSK $1.68
  • 52 Week High
  • SPRO $3.22
  • TUSK $4.90
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 60.07
  • TUSK 43.85
  • Support Level
  • SPRO $1.84
  • TUSK $2.23
  • Resistance Level
  • SPRO $2.05
  • TUSK $2.49
  • Average True Range (ATR)
  • SPRO 0.08
  • TUSK 0.08
  • MACD
  • SPRO 0.03
  • TUSK -0.00
  • Stochastic Oscillator
  • SPRO 85.71
  • TUSK 22.58

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About TUSK Mammoth Energy Services Inc.

Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes well completion services (Well Completion), infrastructure services (Infrastructure) and natural sand proppant services (Sand). Key revenue is generated from Infrastructure which include electric utility infrastructure services to government-funded utilities, private utilities, public investor-owned utilities, etc.

Share on Social Networks: